Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

8.640 -1.670 (-16.20%)
Streaming Delayed Price Updated: 12:55 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,018,493
Open 9.020
Bid (Size) 8.620 (100)
Ask (Size) 8.640 (100)
Prev. Close 10.31
Today's Range 8.520 - 9.310
52wk Range 5.035 - 16.19
Shares Outstanding 43,466,186
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Regenxbio Stock Still Has Over 300% Upside Despite FDA Pushback On Hunter Syndrome Drug: Clear Street ↗
Clear Street pointed to strength in RGX-202 data for Duchenne and early results from Sura-Vec in wet AMD. 
Via Stocktwits
News headline image
Why Did RGNX Shares Plummet 19% After-Hours Today? ↗
REGENXBIO said on Monday that the U.S. Food and Drug Administration (FDA) denied approval for its gene therapy in treating Hunter syndrome, outlining several reasons for the denial. 
Via Stocktwits

Performance

YTD
-36.3%
-36.3%
1 Month
-42.7%
-42.7%
3 Month
-21.6%
-21.6%
6 Month
+15.8%
+15.8%
1 Year
+9.5%
+9.5%

More News

Read More
Monday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
RGNX Shares Pare Losses As Wall Street Dismisses Gene Therapy Clinical Hold Spurred Selloff As An Overreaction ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Analyst Expectations For Regenxbio's Future ↗
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Alerts Investors of REGENXBIO Inc. (RGNX) to an Investigation of Possible Securities Law Violations
Via NewMediaWire
News headline image
Kaplan Fox Alerts Investors of REGENXBIO Inc. (RGNX) to an Investigation of Possible Securities Law Violations
Via TheNewswire.com
Gapping stocks in Wednesday's session ↗
Via Chartmill
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
News headline image
RGNX Stock Is Falling Today — What Is The FDA Update On REGENXBIO's Gene Therapy? ↗
Via Stocktwits
Top movers in Wednesday's pre-market session ↗
Via Chartmill
News headline image
My Top 4 Stocks to Buy in Early 2026 ↗
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
Via MarketMinute
News headline image
REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
REGENXBIO INC (NASDAQ:RGNX) Tops Q3 2025 Estimates, Shares Rise on Strong Results and Pipeline Progress ↗
Via Chartmill
News headline image
The Analyst Verdict: Regenxbio In The Eyes Of 7 Experts ↗
Via Benzinga
News headline image
7 Analysts Assess Regenxbio: What You Need To Know ↗
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Regenxbio Through 6 Analysts ↗
Via Benzinga
News headline image
Regenxbio Unveils 12-Month Data For Gene Therapy Soon After FDA Delays Review Date ↗
Via Benzinga
News headline image
Navigating the Currents: Top Sectors Primed for Growth in Q3 2025
Via MarketMinute
Topics Artificial Intelligence Economy Retirement
News headline image
FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year ↗
Via Benzinga
News headline image
REGENXBIO INC (NASDAQ:RGNX) Reports Q2 2025 Earnings Miss, Stock Slides Amid Revenue and EPS Shortfalls ↗
Via Chartmill
Topics Earnings

Frequently Asked Questions

Is REGENXBIO Inc. - Common Stock publicly traded?
Yes, REGENXBIO Inc. - Common Stock is publicly traded.
What exchange does REGENXBIO Inc. - Common Stock trade on?
REGENXBIO Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for REGENXBIO Inc. - Common Stock?
The ticker symbol for REGENXBIO Inc. - Common Stock is RGNX on the Nasdaq Stock Market
What is the current price of REGENXBIO Inc. - Common Stock?
The current price of REGENXBIO Inc. - Common Stock is 8.640
When was REGENXBIO Inc. - Common Stock last traded?
The last trade of REGENXBIO Inc. - Common Stock was at 02/10/26 12:55 PM ET
What is the market capitalization of REGENXBIO Inc. - Common Stock?
The market capitalization of REGENXBIO Inc. - Common Stock is 375.55M
How many shares of REGENXBIO Inc. - Common Stock are outstanding?
REGENXBIO Inc. - Common Stock has 376M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.